FR23C1024I1 - Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois - Google Patents

Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois

Info

Publication number
FR23C1024I1
FR23C1024I1 FR23C1024C FR23C1024C FR23C1024I1 FR 23C1024 I1 FR23C1024 I1 FR 23C1024I1 FR 23C1024 C FR23C1024 C FR 23C1024C FR 23C1024 C FR23C1024 C FR 23C1024C FR 23C1024 I1 FR23C1024 I1 FR 23C1024I1
Authority
FR
France
Prior art keywords
pthrp
analog
stable composition
bone protein
anabolic bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1024C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Radius Health Inc
Original Assignee
Ipsen Pharma SAS
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1024(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Pharma SAS, Radius Health Inc filed Critical Ipsen Pharma SAS
Publication of FR23C1024I1 publication Critical patent/FR23C1024I1/fr
Application granted granted Critical
Publication of FR23C1024I2 publication Critical patent/FR23C1024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
FR23C1024C 2006-10-03 2023-06-05 Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois Active FR23C1024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
PCT/US2007/021216 WO2008063279A2 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (2)

Publication Number Publication Date
FR23C1024I1 true FR23C1024I1 (fr) 2023-07-21
FR23C1024I2 FR23C1024I2 (fr) 2024-06-14

Family

ID=39430237

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1024C Active FR23C1024I2 (fr) 2006-10-03 2023-06-05 Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois

Country Status (28)

Country Link
US (1) US8148333B2 (pt)
EP (2) EP2957278B1 (pt)
JP (1) JP5375611B2 (pt)
KR (4) KR101512377B1 (pt)
CN (2) CN102274492B (pt)
AU (1) AU2007322334B2 (pt)
BR (2) BRPI0719821B8 (pt)
CA (1) CA2664734C (pt)
CY (1) CY1119198T1 (pt)
DK (2) DK2073789T3 (pt)
ES (2) ES2739459T3 (pt)
FR (1) FR23C1024I2 (pt)
HK (1) HK1214181A1 (pt)
HR (1) HRP20171217T1 (pt)
IL (1) IL197926A (pt)
LT (1) LT2957278T (pt)
MX (1) MX2009003569A (pt)
NL (1) NL301235I2 (pt)
NO (1) NO344885B1 (pt)
NZ (1) NZ576682A (pt)
PL (1) PL2957278T3 (pt)
PT (2) PT2957278T (pt)
RS (1) RS56164B1 (pt)
RU (1) RU2506070C2 (pt)
SG (1) SG175580A1 (pt)
SI (1) SI2957278T1 (pt)
UA (1) UA98776C2 (pt)
WO (1) WO2008063279A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739459T3 (es) 2006-10-03 2020-01-31 Radius Health Inc Una composición estable que comprende una proteína anabólica ósea, es decir un análogo de PTHrP y usos de la misma
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
LT2568806T (lt) 2010-05-12 2016-09-26 Radius Health, Inc. Terapiniai režimai
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
RU2013151314A (ru) 2011-04-22 2015-05-27 Радиус Хэлс, Инк. СПОСОБ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ РТН, РТНrР И РОДСТВЕННЫХ ПЕПТИДОВ
KR101891673B1 (ko) * 2011-06-07 2018-08-27 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
CA2857501C (en) 2011-11-30 2020-06-23 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
US20180161401A1 (en) * 2015-07-06 2018-06-14 Zheng Xin Dong Novel Formulations of PTHrP Analogue
TWI659991B (zh) 2015-08-31 2019-05-21 Rohm And Haas Electronic Materials Llc 與外塗佈光致抗蝕劑一起使用的塗料組合物
EP3359241B1 (en) * 2015-10-09 2021-04-14 Radius Health, Inc. Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
ES2904891T3 (es) 2016-04-18 2022-04-06 Radius Health Inc Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
AU2019297421A1 (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) * 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
CN1070500C (zh) 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) * 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) * 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
KR100679778B1 (ko) 1997-09-09 2007-02-07 에프. 호프만-라 로슈 아게 PTHrP 유사체를 사용하는 골절 치료법
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
AU2003251527A1 (en) * 2002-06-13 2003-12-31 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
CA2511966A1 (en) 2002-11-01 2004-07-22 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
ES2739459T3 (es) 2006-10-03 2020-01-31 Radius Health Inc Una composición estable que comprende una proteína anabólica ósea, es decir un análogo de PTHrP y usos de la misma
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog

Also Published As

Publication number Publication date
CN101578093A (zh) 2009-11-11
WO2008063279A3 (en) 2009-06-25
SG175580A1 (en) 2011-11-28
BRPI0719821B1 (pt) 2020-04-14
PL2957278T3 (pl) 2017-10-31
CN102274492B (zh) 2014-11-26
RU2009116531A (ru) 2010-11-10
KR20170067906A (ko) 2017-06-16
MX2009003569A (es) 2009-08-25
CA2664734C (en) 2023-08-01
CN102274492A (zh) 2011-12-14
RS56164B1 (sr) 2017-11-30
NO20091545L (no) 2009-05-27
BRPI0722428A2 (pt) 2013-11-26
WO2008063279A2 (en) 2008-05-29
US8148333B2 (en) 2012-04-03
KR20090083350A (ko) 2009-08-03
FR23C1024I2 (fr) 2024-06-14
RU2506070C2 (ru) 2014-02-10
CA2664734A1 (en) 2008-05-29
EP2073789B8 (en) 2022-09-14
KR101512377B1 (ko) 2015-04-28
IL197926A0 (en) 2011-08-01
EP2073789A2 (en) 2009-07-01
AU2007322334A1 (en) 2008-05-29
EP2073789B1 (en) 2019-05-22
ES2739459T3 (es) 2020-01-31
NZ576682A (en) 2012-08-31
CY1119198T1 (el) 2018-02-14
BRPI0719821B8 (pt) 2021-05-25
NO344885B1 (no) 2020-06-15
UA98776C2 (ru) 2012-06-25
AU2007322334B2 (en) 2011-12-22
HRP20171217T1 (hr) 2017-10-20
DK2073789T3 (da) 2019-08-05
SI2957278T1 (sl) 2017-09-29
KR20180117738A (ko) 2018-10-29
ES2637283T3 (es) 2017-10-11
BRPI0719821A2 (pt) 2013-05-07
JP2010505835A (ja) 2010-02-25
WO2008063279A9 (en) 2008-07-10
KR20150020289A (ko) 2015-02-25
LT2957278T (lt) 2017-09-11
EP2957278A1 (en) 2015-12-23
PT2957278T (pt) 2017-08-23
NL301235I2 (nl) 2023-08-31
US20100029556A1 (en) 2010-02-04
IL197926A (en) 2014-08-31
CN101578093B (zh) 2011-09-14
HK1214181A1 (zh) 2016-07-22
DK2957278T3 (en) 2017-07-31
EP2957278B1 (en) 2017-05-17
PT2073789T (pt) 2019-07-31
JP5375611B2 (ja) 2013-12-25

Similar Documents

Publication Publication Date Title
FR23C1024I1 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
EP1986674A4 (en) PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
BRPI0813699A2 (pt) Formulações de proteína de fusão glp-1-fc
IL218357A0 (en) Compositions and methods of using angiopoietin-like 4 protein
EP1874334A4 (en) COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
EP1487488A4 (en) SPECIFIC ANTIBODIES AGAINST AMYLOID BETA PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP1765379A4 (en) CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
EP1890720A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING PEPTIDES DERIVED FROM CASEIN AND METHODS OF USE THEREOF
ZA200900379B (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
EP1855719A4 (en) NEUTRALIZING MONOCLONAL ANTIBODIES TO CORONAVIRES IN CONNECTION WITH HEAVY ACUTE RESPIRATORY SYNDROME
IL188288A0 (en) Polypeptide having an activity of suppressing food intake and pharmaceutical compositions containing the same
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
DE602006007995D1 (de) Formulierungen von liponsäure und hyaluronsäurebeneichen
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
FR2925500B1 (fr) Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
FR2932680B1 (fr) Association de tiliroside et d'un peptide
WO2004081031A3 (en) Thiol-mediated drug attachment to targeting peptides
FR2946340B1 (fr) Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
HUP0600489A2 (en) Use of echinacea or preparations made thereof for the manufacture of pharmaceutical compositions for the treatment of anxiety
FR2889050B1 (fr) Analogue d'implant dentaire
ZA200710374B (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof